查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球激素替代療法 (HRT) 市場
市場調查報告書
商品編碼
1140670

2022-2029 年全球激素替代療法 (HRT) 市場

Global Hormone Replacement Therapy (HRT) Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

到 2021 年，激素替代療法 (HRT) 市場價值將達到 145.535 億美元。預計在預測期內（2022-2029 年）將以 5.1% 的複合年增長率增長。

激素替代療法 (HRT) 是一種替代或替代體內不足以達到正常生理所需水平的激素的技術。激素替代療法有助於平衡絕經期間或接近絕經期的雌激素和孕激素水平。在更年期、激素治療或更年期激素治療期間，激素替代療法可以幫助緩解潮熱、出汗和其他更年期症狀。 HR 療法也被證明可以預防絕經後婦女的骨質流失和減少骨折。全身激素療法以片劑、乳膏、噴霧劑、皮膚貼劑和凝膠的形式出現，是緩解更年期潮熱和盜汗的最有效療法之一。

市場動態

激素替代療法市場的增長受到主要因素的推動，例如女性更年期意識的提高、新給藥系統的藥物開發增加以及與人口老齡化相關的激素失衡增加。

隨著老年人口的增加，荷爾蒙失調的加劇正在推動 HRT 市場的增長

隨著老年人口的增加，荷爾蒙失調症是推動 HRT 市場增長的主要因素之一。由於一些荷爾蒙的變化，女性身體主要受到自然衰老過程的影響，導致異常和疾病。常見問題包括疲勞、體重增加、記憶力減退、性慾下降、外觀老化和肌肉損失。

由於與年齡相關的荷爾蒙變化，最常見的情況與更年期有關。全球女性絕經的平均年齡約為 50 歲。在女性中，雌激素和孕激素水平在 50 歲後顯著下降。這種雌激素和孕激素分泌的減少由垂體補償，垂體增加促卵泡激素 (FSH) 的分泌。這以潮熱的形式表現出來，這是更年期的症狀。

激素替代療法的發展增加

激素替代療法市場在過去幾年經歷了顯著發展，預計在預測期內將出現顯著增長。隨著荷爾蒙失調問題的頻率增加以及年齡和新生兒人口的增加，預計這些疾病將繼續發展。常規觀察細節的存在、藥物輸送框架領域的技術進步以及患者意識的提高推動了對激素替代療法的日益濃厚的興趣。更年期女性是影響市場的最大部分，預計 45-59 歲女性人口的增加和更年期窗口的擴大將推動發展。

2020 年 1 月，加利福尼亞州推出了一項新的更年期健康服務，首次為女性提供遠程醫療諮詢和更年期激素替代療法的遠程醫療處方。這個名為 CurieMD 的遠程醫療平台為消費者提供與董事會認證的中年健康從業者的視頻諮詢（免費開始，後續預約 39 美元）。 FDA 批准的生物同質激素療法可作為口服片劑、陰道乳膏、口服避孕藥和季度付款計劃使用。

與 HRT 相關的副作用和風險可能會阻礙市場增長

激素替代療法有一些副作用，包括消化不良、抑鬱、體液瀦留和頭痛。預計這些副作用會阻礙這種療法的採用。

激素替代療法可能會給患有不受控制的高血壓、血栓形成、血液甘油三酯水平、中風、心髒病、乳腺癌和膽囊疾病的人帶來多種風險。

此外，根據英國 NICE 的調查結果，激素替代療法與黃體酮和雌激素藥物聯合使用時會增加患乳腺癌的風險。長期使用 HRT 藥物也可能增加血栓的風險。一項研究發現，每 1,000 名服用 HRT 片劑 7.5 年的女性中，只有不到 2 名出現血栓。

流行病學

甲狀腺功能減退。

全國健康和營養檢查調查 (NHANES 1999-2002) 報告稱，在代表美國的 4392 名甲狀腺功能減退症患者中，有 3.7% 的人患有甲狀腺功能減退症（定義為 TSH 水平 >4.5 mIU/L）。甲狀腺功能減退症在出生時體型較小且兒童時期肥胖程度較低的女性中更為常見。

導致甲狀腺功能減退的碘缺乏症在最不發達國家更為常見。定期用碘補充鹽、麵粉和其他主食已降低碘缺乏率。

世界衛生組織 (WHO) 在 1994 年 1 月至 2006 年 12 月期間針對 130 個國家/地區的數據發現，30.6% 的人口碘營養不足。 WHO 建議一般人群的尿碘濃度範圍為 100-199 hoshi g/L，孕婦的尿碘濃度範圍為 150-249 hoshi g/L。

甲狀腺功能減退、甲狀腺腫和甲狀腺結節的頻率隨著年齡的增長而增加。甲狀腺功能減退症在老年人中最常見，2-20% 的老年人群患有某種形式的甲狀腺功能減退症。在 Framingham 研究中，5.9% 的 60 歲及以上女性和 2.4% 的男性患有甲狀腺功能減退症（TSH >10 mIU/L）。在 NHANES 1999-2002 中，80 歲以上的人患甲狀腺功能減退症的可能性是 12-49 歲的人的五倍。

NHANES 1999-2002 報告說，白種人 (5.1%) 和墨西哥裔美國人的甲狀腺功能減退症患病率高於非洲裔美國人 (1.7%)。非裔美國人的 TSH 水平中值也往往較低。

市場細分

全球激素替代療法 (HRT) 市場根據產品、疾病類型、給藥途徑和分銷渠道進行細分。

根據疾病，預計在預測期內更年期將以高複合年增長率增長

更年期是月經週期結束的階段。 12個月未來月經時診斷。更年期發生在 40 或 50 歲。更年期是一個自然的生物過程。激素替代療法，無論是在更年期還是更晚開始，都可以提高老年女性的生活質量並延長壽命。這種療法有助於老年婦女維持雌激素水平。

隨著全球老齡化人口的增加，絕經期的增長預計會增加。聯合國估計，到 2020 年，全球將有 9.8 億女性年齡在 50 歲以上。可以進一步估計，到 2050 年，這一數字將增加到 16.5 億。到 2020 年，51 歲以上的美國女性將超過 5000 萬。預計這種變化在發達國家會更加明顯。因此，隨著男性和女性年齡的增長，HRT 對老年女性的應用有望擴大，從而導致市場增長。

根據美國婦產科學院的數據，每天約有 6,000 名女性經歷更年期。多個品牌和仿製藥的存在以及女性意識的提高預計將成為提色增強因素的重大影響。

按產品劃分，預計在預測期內雌激素細分市場將佔據最大的市場份額。

HRT 市場按產品細分為雌激素、睪酮、人類生長激素和甲狀腺激素療法。其中，雌激素替代療法部分將在 2021 年佔據最大的市場份額，因為基於雌激素的產品已被研究以產生最多的處方。雌激素替代療法用於絕經後和子宮切除術的婦女，以幫助維持荷爾蒙平衡。

另一方面，人類生長激素療法預計在預測期內以最快的複合年增長率增長，尤其是由於嬰兒生長障礙的發生率不斷增加。例如，根據世衛組織贊助的一項研究，約有 1500 萬新生兒早產，其中約 85% 未完全發育。激素療法也用於成人治療短腸綜合徵和垂體瘤等疾病。

區域介紹

北美在全球激素替代療法市場中佔有最大的市場份額。

由於美國和加拿大的老年人口不斷增加，北美地區將在 2021 年佔據全球激素替代療法市場的最大份額。根據美國國立衛生研究院 (NIH) 的數據，美國近一半的絕經後婦女報告說，她們一生中至少使用過一次激素替代療法。含有雌激素和選擇性雌激素受體調節劑的結合馬雌激素 (CEE)/巴多昔芬片劑在美國上市，用於治療絕經期 VMS 和預防骨質疏鬆症。總體而言，由於女性越來越多地採用激素替代療法進行絕經後和更年期管理，預計美國激素替代療法市場在預測期內將出現高速增長。

亞太地區是全球激素替代療法增長最快的市場

預計亞太地區 HRT 市場將在 2022-2029 年的預測期內出現最快的增長。醫療保健專業人員對對抗激素缺乏症的認識和興趣的提高預計將推動該地區的市場增長。

競爭格局。

激素替代療法市場正在鞏固和競爭。為市場增長做出貢獻的主要參與者包括雅培、輝瑞、拜耳、諾華、艾爾建、諾和諾德、Mylan NV、F. Hoffmann-La Roche、禮來公司等。領先的公司正在採取多種增長戰略，例如產品發布、收購和合作夥伴關係，這有助於全球激素替代療法市場的增長。例如，2019 年 11 月 23 日，Theramex 獲得了 Janssen 的 Evorel 貼片的世界版權。此次收購的目的是意識到 HRT 供應鏈短缺，並專注於解決這一問題。

雅培實驗室

概述

Abbott Laboratories 是一家總部位於美國的全球醫療器械和醫療保健公司。它有四個業務部門：醫療設備、診斷、品牌仿製藥和營養產品。 2013 年，我們將研究藥物業務拆分為 AbbVie。 2020 年 3 月，雅培獲得了 FDA 的緊急使用授權（ EUA ），用於 2019 版 nCoV 測試，以幫助緩解 COVID-19大流行。

COVID-19 影響分析

COVID-19 正在通過對生產和需求的直接影響、供應鏈中斷和市場中斷以及對企業和金融市場的財務影響來影響全球經濟。隨著越來越多的利益相關者尋求新的方法來診斷和治療感染 COVID-19 的患者，全球激素替代療法 (HRT) 市場受到了 COVID-19 流行病的影響。

外源性雌激素和睪酮療法具有治療潛力，可以減輕對 SARS-CoV-2 的有害炎症反應，而不會干擾免疫系統對病毒（如皮質類固醇）的反應。使用阻斷炎症標誌物受體的免疫調節劑（例如 anarka [IL-1 受體阻斷劑]、托珠單抗和 sarilumab）來減輕對 SARS-CoV-2 的放大和組織損傷性免疫反應。[IL-6 受體拮抗劑] ）。然而，人們擔心這些藥物可能會對患者的免疫功能產生不利影響。

倫敦國王學院、利物浦大學、佐伊全球有限公司的一項研究將女性的高雌激素水平與低 COVID-19 感染和嚴重程度聯繫起來，旨在幫助評估雌激素治療潛力 我們檢查了性別的存在與否。

結果顯示，服用 HRT 的絕經後婦女對 COVID-19 的預測率更高，相關症狀的發生頻率也更高，但並未住院。 HRT 的使用與較低的呼吸支持和陽性檢測趨勢相關。年齡組分析顯示，55-60 歲年齡組獲益最大。

研究人員調查了複合口服避孕藥 (COCP) 形式的外源性雌激素對 COVID-19 相關症狀和感染的影響，以及絕經後婦女對 COVID-19 的激素替代療法 (HRT) 的影響。還檢查了症狀的嚴重程度。

未來，有必要研究激素替代療法是否在治療被診斷患有 COVID-19 的老年人中發揮藥物治療作用。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按產品劃分的市場細分
  • 按疾病類型劃分的市場細分
  • 按管理途徑劃分的市場細分
  • 按分銷渠道劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
  • 驅動程序
    • 提高女性對絕經後問題的認識
    • 通過新的遞送系統增加藥物開發
  • 限制因素
    • 激素替代療法費用高
  • 商機
  • 影響分析

第5章行業分析

  • 波特五力分析
  • 管道分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 保險報銷分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品分類

  • 甲狀腺激素替代療法
  • 雌激素替代療法
  • 雄性激素替代療法
  • 人類生長激素替代療法

第 8 章人類生長激素替代療法

  • 甲狀腺功能減退
  • 更年期
  • 男性性腺機能減退
  • 生長激素缺乏症
  • 其他

第 9 章給藥途徑

  • 口語
  • 腸胃外
  • 透皮給藥
  • 其他

第10章分銷渠道

  • 醫院藥房
  • 零售藥店和藥店
  • 在線藥店
  • 其他

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 13 章公司簡介

  • 雅培實驗室
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Pfizer, Inc.
  • Bayer AG
  • Novartis AG
  • Allergan Plc
  • Novo Nordisk A/S
  • Mylan NV
  • F. Hoffmann-La Roche
  • Eli Lilly and Company
  • Noven Pharmaceuticals, Inc.（List Not Exhaustive）

第14章 DataM

簡介目錄
Product Code: DMPH2744

Market Overview

Hormone Replacement Therapy (HRT) market was valued at USD 14,553.5 million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 5.1% during the forecast period (2022-2029).

Hormone replacement therapy (HRT) is a technique for replacing and replenishing hormones in the human body, which are at inadequate levels than those required for the normal physiology of the human body. Hormone replacement therapy helps to balance the estrogen and progesterone levels during or near menopause. During menopause, hormonal therapy or menopausal hormone therapy, hormone replacement therapy helps to relieve hot flashes, sweating, and other symptoms of menopause. HR therapy has also been proved to prevent bone loss and reduce fracture in postmenopausal women. Systemic hormone therapy which comes in pill, cream, spray form, skin patch, or gel is one of the most effective treatments for the relief of menopausal hot flashes and night sweats.

Market Dynamics

The hormone replacement therapy market growth is driven by some of the major factors such as growing awareness of post-menopausal issues among women, increasing drug development with novel delivery systems, and hormonal imbalance disorders with the growing geriatric population.

Rising hormonal imbalance disorders with a growing geriatric population drive the HRT market growth

Hormonal imbalance disorders, with a growing geriatric population, is one of the major factors driving the growth of the HRT market. With several hormonal changes, the female body predominantly gets affected by the natural process of aging, which leads to abnormalities and diseases. Some of the common problems include fatigue, weight gain, memory decline, low libido, aging appearance, and muscle loss.

The most frequent consequence of age-related hormonal changes occurs in cases related to menopause. The global average onset age for menopause among women is approximately 50 years. In women, the production levels of estrogen and progesterone decrease significantly by the age of 50 years and above. This decrease in production levels of estrogen and progesterone is compensated by the pituitary gland, with the increased production of follicle-stimulating hormone (FSH). This is physically manifested in women in the form of post-menopause symptoms, which include flush.

Increasing Development in the Hormone Replacement Therapy

The hormone replacement therapy market has observed significant development over the past few years and is expected to grow significantly during the forecast period. With the increasing frequencies of hormonal lopsidedness issues and expanding age and the neonatal populace, these sicknesses are foreseen to advance development. The rising interest in hormone replacement therapy is driven by the existence of routinely observed details, growing technological progression in the field of drug delivery frameworks, and rising awareness among patients. Menopausal females frame the biggest segment influencing the market and subsequently, the rising female populace between the age gathering of 45 to 59 and expanding the scope of the menopausal window are anticipated to push development.

In January 2020, a new menopause health service has launched in California that offers women remote consultations and, for the first time, mail-order prescriptions of menopause hormone replacement therapies. The telemedicine platform, called CurieMD, offers consumers video consultation with a board-certified midlife health practitioner (free at launch, and $39 for follow-up appointments). The FDA-approved bio-identical hormone treatments on offer come as oral tablets, vaginal creams, and oral contraceptive pills, and are offered as quarterly payment plans.

Side effects and risks associated with HRT might hamper the market growth

Hormone Replacement Therapy has several side effects such as indigestion, depression, fluid retention, headache, among others. These side effects are anticipated to hamper the adoption of this therapy.

Hormone replacement therapy might cause some risks for people with uncontrolled hypertension, or high blood pressure, thrombosis or blood clots, high levels of triglycerides in the blood, stroke, heart disease, breast cancer, and gallbladder disease.

Also, according to a UK-based NICE finding, hormone replacement therapy is associated with breast cancer risk if the drugs progesterone and oestrogen are taken in combination. Prolonged consumption of HRT drugs might lead to an increased risk of blood clots also. Every 1,000 women taking HRT tablets for 7.5 years, less than two will develop a blood clot, as per some studies.

Epidemiology

Hypothyroidism:

According to the National Health and Nutrition Examination Survey (NHANES 1999-2002), of 4392 individuals reflecting the US population reported hypothyroidism (defined as TSH levels exceeding 4.5 mIU/L) in 3.7% of the population. Hypothyroidism is most common in women with small body size at birth and low body mass index during childhood.

Iodine deficiency as a cause of hypothyroidism is more common in less-developed countries. Routine supplementation of salt, flour, and other food staples with iodine has decreased the rates of iodine deficiency.

The World Health Organization (WHO) data from 130 countries taken from January 1994 through December 2006 found inadequate iodine nutrition in 30.6% of the population. The WHO recommends urinary iodine concentrations between 100 and 199 μg/L in the general population and a range of 150-249 μg/L in pregnant women.

The frequency of hypothyroidism, goiters, and thyroid nodules increases with age. Hypothyroidism is most prevalent in elderly populations, with 2-20% of older age groups having some form of hypothyroidism. The Framingham study found hypothyroidism (TSH > 10 mIU/L) in 5.9% of women and 2.4% of men older than 60 years. In NHANES 1999-2002, the odds of having hypothyroidism were five times greater in persons aged 80 years and older than in individuals aged 12-49 years.

The NHANES 1999-2002 reported that the prevalence of hypothyroidism was higher in whites (5.1%) and Mexican Americans than in African Americans (1.7%). The African Americans tend to have lower median TSH values.

Market Segmentation

The global hormone replacement therapy (HRT) market is segmented based on the product, disease type, route of administration, and distribution channel.

Based on Disease, Menopause is Expected to Growth at High CAGR over the Forecast Period

Menopause is the stage that marks the end of the menstrual cycle. It is diagnosed after 12 months without a menstrual period. Menopause can happen at the age of 40 or 50. Menopause is a natural biological process. Hormone replacement therapy improves the quality of life and prolongs life for elderly women, whether it is initiated at menopause or much later. The therapy helps elderly women maintain their estrogen levels.

The menopause segment growth is expected to increase as the geriatric population globally increases. The United Nations has estimated that 980 million women globally in 2020 are aged 50 and over. This figure can be further estimated to rise to 1.65 billion by 2050. In 2020, the number of United States women aged older than 51 years was expected to be more than 50 million. This change is expected to be more prevalent in developed countries. Hence, as both men and women age, the application of HRT in older women is expected to grow, which will help the market growth.

As per the American Congress of Obstetricians and Gynecologists, about 6,000 women reach menopause daily. The presence of several branded and generic drugs and growing awareness among women are expected to be the vital impact of rendering drivers.

By Product, Estrogen Segment is Expected to Hold Largest Market Share During the Forecast Period

Based on product, the HRT market is segmented into therapies for estrogen, testosterone, human growth hormone, and thyroid hormones. Among these, the estrogen hormone replacement therapy segment accounted for the largest market share in 2021, as estrogen-based products have been studied to generate the largest number of prescriptions. Estrogen replacement therapy is used in women during post-menopause or hysterectomy, which helps them to maintain the hormonal balance.

On the other hand, the human growth hormone therapy is expected to grow at the fastest CAGR over the forecast period due to the increasing incidences of growth deficiencies, especially in infants. For instance, as per a survey organized by the WHO, around 15 million newborns are born premature, and around 85% of these infants are not fully developed. In adults, hormone therapy is provided for conditions such as short bowel syndrome and pituitary tumors.

Geographical Presentation

North America region holds the largest market share in the global Hormone Replacement Therapy market

North America region is dominating the global hormone replacement therapy market accounted for the largest market share in 2021, owing to the growing geriatric population in the United States and Canada. As per the National Institutes of Health (NIH), almost half of all the post-menopausal women in the United States reported having used hormone replacement therapy at least once in their life. The conjugated equine estrogens (CEE)/bazedoxifene tablet, a combination of estrogen and a selective estrogen receptor modulator, is available in the U.S. for menopausal VMS treatment and osteoporosis prevention. Overall, the market for hormone replacement therapy in the United States is scheduled for high growth over the forecast period, due to the growing adoption of hormone replacement therapy among women, for both post-menopausal and menopause management.

The Asia Pacific is the fastest-growing market in the global hormone replacement therapy market

The Asia Pacific HRT market is expected to witness the fastest growth over the forecast period from 2022 to 2029. Increasing awareness levels and the rising focus of healthcare providers on the eradication of hormonal deficiencies are expected to boost the growth of the market within the region.

Competitive Landscape:

The hormone replacement therapy market is consolidated and competitive. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Pfizer, Inc., Bayer AG, Novartis AG, Allergan Plc, Novo Nordisk A/S, Mylan NV, F. Hoffmann-La Roche, Eli Lilly, and Company, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the hormone replacement therapy market globally. For instance, on 23rd November 2019, Theramex acquired global rights to Janssen's Evorel patches. This acquisition aims needs to be aware of the supply chain of HRT shortages and is dedicated to resolving this issue.

Abbott Laboratories

Overview:

Abbott Laboratories headquarters in the United States is a global medical device and health care company. The company has four business segments: medical devices, diagnostics, branded generic medicines, and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013. In March 2020, Abbott received emergency use authorization (EUA) from the FDA for a 2019-nCoV test to help mitigate the COVID-19 pandemic.

COVID-19 Impact Analysis

The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets. The global hormone replacement therapy (HRT) market has been impacted by the COVID-19 pandemic, as stakeholders are increasingly searching for newer approaches towards diagnosing and curing patients affected by the COVID-19.

Exogenous estrogen and testosterone therapies have a therapeutic potential to mitigate the damaging inflammatory response to SARS-CoV-2 without hampering the immune system's response to the virus as corticosteroids do. The use of immune-modulating drugs to block inflammatory markers' receptors to mitigate the amplified and tissue-damaging immune response of SARS-CoV-2 (eg, anarka [an IL-1 receptor blocker] and tocilizumab and sarilumab [IL-6 receptor antagonists]). However, there are concerns about these agents' possible adverse effects on the patient's immune function.

According to research from King's College London, the University of Liverpool, and Zoe Global Limited, aimed at contributing to an evaluation of the potential for estrogen treatment in COVID-19, by examining the presence of an association between high estrogen levels and lower levels of COVID-19 infection and severity in women.

The researchers showed that the rate of predicted COVID-19 was higher in postmenopausal women on HRT, who also showed a higher frequency of related symptoms but not of hospitalization. HRT use was associated with a trend towards lower respiratory support and positive testing. The age-group analysis showed the effects to be highest in the 55-60-year age group.

The researchers also looked at the effect of exogenous estrogen in the form of the combined oral contraceptive pill (COCP) on COVID-19-related symptoms and infection, and the effect of hormone replacement therapy (HRT) on COVID-19 positivity and symptom severity in women past menopause.

There is a need for future research to examine whether hormone replacement therapy may have a pharmacotherapeutic role in treating older adults diagnosed with COVID-19.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by Disease Type
  • 3.3. Market Snippet by Route of Administration
  • 3.4. Market Snippet by Distribution Channel
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Growing Awareness on Post-menopausal Issues among Women
    • 4.2.2. Increasing Drug Development with Novel Delivery Systems
    • 4.2.3. XX
  • 4.3. Restraints
    • 4.3.1. High Cost of Hormone Replacement Therapy
    • 4.3.2. XX
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Pipeline Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
    • 7.1.2. Market Attractiveness Index, By Product Segment
  • 7.2. Thyroid Hormone Replacement Therapy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3. Estrogen Hormone Replacement Therapy
  • 7.4. Testosterone Hormone Replacement Therapy
  • 7.5. Human Growth Hormone Replacement Therapy

8. Human Growth Hormone Replacement Therapy

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
    • 8.1.2. Market Attractiveness Index, By Disease Type Segment
  • 8.2. Hypothyroidism*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3. Menopause
  • 8.4. Male Hypogonadism
  • 8.5. Growth Hormone Deficiency
  • 8.6. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 9.3. Parenteral
  • 9.4. Transdermal
  • 9.5. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
    • 10.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies and Drugstores
  • 10.4. Online Pharmacy
  • 10.5. Others

11. By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Abbott Laboratories*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Pfizer, Inc.
  • 13.3. Bayer AG
  • 13.4. Novartis AG
  • 13.5. Allergan Plc
  • 13.6. Novo Nordisk A/S
  • 13.7. Mylan NV
  • 13.8. F. Hoffmann-La Roche
  • 13.9. Eli Lilly and Company
  • 13.10. Noven Pharmaceuticals, Inc. (List Not Exhaustive)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us